The risk for inflammatory bowel disease is higher in patients with psoriasis or ankylosing spondylitis using IL-17A inhibitors than in those using apremilast, necessitating careful patient monitoring.

IBD is a chronic condition characterized by inflammation ... SPY003 demonstrated equivalent potency to risankizumab in inhibiting pSTAT signaling and IL-17 production and exhibited significantly ...